 Cyclo Therapeutics Inc NASDAQ: CYTH has commenced its pivotal Phase 3 study TransportNPC evaluating Trappsol Cyclo for Niemann-Pick Disease Type C1 NPC1. The TransportNPC study has the regulatory and IRB approval required to commence patient enrollment, and site activation is underway. 